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Executive Summary
In the last several years, genetic sequencing technologies have become widely
accessible to consumers as prices have fallen at rates faster than the National Institute of
Health had initially predicted. With these lower costs more patients now have access to their
own genetic information than ever before, thanks to a host of new services.
Though objective in itself, genetic information is often regarded as an a indicator of
social and medical outcomes, with some associations substantiated and others largely reflecting
social attitudes. Our understanding of genetic markers as forecasters for certain psychological
and physiological disorders is still relatively limited, but associations between certain genes and
certain outcomes, however scientifically valid, hold the potential to yield disparate treatment
through this new facet of human diversity. There is some concern that this growing library of
information is portentous to discrimination in employment and insurance coverage based on
these genetic differences; for this reason lawmakers have attempted to alleviate fears of such
socially deterministic practices. The Genetic Indiscrimination Act of 2008 (GINA) amends much
of these privacy concerns through a series of far-reaching legal protections, however lacunae
remain both in the law's language and in the inherent traceability of genetic information itself.
In this report the author will attempt to address why GINA and its counterparts came into
being, what kinds of protections they offer, and where they might be improved to benefit the
individuals they were written to protect. Some states have attempted to expand on Federal law
to address life, longterm care, and disability insurance, however the absence of a current
authoritative source on the statutes of all 50 states may hinder the ability of patients to utilize
these additional protections. The author also found that some privacy risks may exist in the
public disclosure of genomes by a patient's relatives, as genetic technology may allow this
information to be used to identify themselves and others whose genomes are listed
anonymously in medical databases. Since an individual's genetic information may reveal traits
present in other family members, this paper also discusses current GINA/HIPAA disclosure
policies, and their shortcomings in providing the genomic information of one patient to others
who may medically benefit from this knowledge.
This report concludes that there are some immediate steps that lawmakers and medical
professionals could take to better protect individuals from discriminatory practices– largely
through education and the expansion of Federal law to cover other forms of insurance. Several
other issues addressed here may not be resolved through immediate changes in policy, but may
end up being reconciled in court in the ensuing years. In addressing these issues, this paper
attempts to evince how discourse among policymakers, scientists, and ethicists has influenced
genetic disclosure policy, what this means for current law, and how this may affect future legal
outcomes.
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Introduction
The human genome was first decoded in its entirety more than a decade ago, and since
that time the availability of whole genome sequencing (WGS) has increased dramatically.
Indeed a service that once cost the U.S. government a 2.7 billion dollar investment over ten
years, is now available to patients for thousands of dollars in a matter weeks. However with this
technology have come a host of concerns over how a growing body of genetic information
should be handled, and who should have the right to access this data. Several laws have been
passed in an effort to prevent this information from being used in discriminatory practices,
however in these early stages of implementation, relatively little is known about their
effectiveness and where they could be improved.
This report will analyze how legal and ethical precepts have interacted with the inherent
qualitative nature of genetic information, to better understand what current policies are most
salient and where such protections have otherwise fallen short. This paper will address the
following questions- (1) Why is the legal protection of genetic information increasingly relevant
in society today? (2) How has a historical legacy of eugenics informed these protections? (3)
What is genetic discrimination and what entitlements are extended to patients by the Federal
“Genetic Information Nondiscrimination Act of 2008”? And (4) how might this law and its related
counterparts be improved upon in the future? Through these questions this report attempts to
evince some of the unresolved challenges genetic services will pose to policymakers in the
years ahead.
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Background
After more than a decade's work, the Human Genome Project released the first fullysequenced human genome in 2001; it was a groundbreaking accomplishment for science and
society alike, representing the dedication of thousands of researchers and funding in excess of
2.7 billion dollars ("The Human Genome Project Completion", 2010). Symbolically this was the
first time that mankind could consider the very building blocks that make up every human being,
and though the first sequences represented but a handful of individuals, their unveiling opened
a proverbial Pandora's box of medical ethics. Human beings are, on average, 99.5% genetically
similar, a smaller margin than geneticists had initially anticipated prior to the Human Genome
Project (Wade 2007). Though half a percent may seem insignificant at its face, this proportion of
genetic difference still represents roughly 150 million base pairs of codons1 out of the 3 billion
which make up an individual's genetic code. It is these base pair differences that comprise the
sum of all human diagnostic genomics.

1

The nucleobase letters A, T, C, & G which comprise deoxyribonucleic acid or “DNA”.
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The Growing Role of Genetic Services
The importance of genetic law has grown significantly in the lives of everyday citizens
as the cost for each genomic transcription has dropped at a pace surpassing even the
predictions of Moore's Law; i.e. the cost of mapping the entire genome of an individual has
decreased faster than a logarithmic rate. A full genome analysis that would have cost roughly
$10 million dollars on average in 2007, had fallen to a modest $8000 average by 2014; in a
matter of several years, technology once reserved for the budgets of entire institutions had
become a medical tool available to most patients ("DNA Sequencing Costs" 2014)2. In some
instances the costs of whole genetic sequencing have fallen well-below $1000 and one
company, 23andMe, has launched partial genome screening kits for ancestry and health for
$993 (Gutierrez 2013; "Whole Genome Sequencing Rates" 2015).
Francis De Souza, president of biotech equipment manufacturer Illumina, Inc., posits
that with current dropping costs in consumer genetic testing, the number of human genomes
completely sequenced has reached approximately 228,000 as of 2014, and at the current rate
of growth this number is projected to double over the next several years, purportedly "reaching
1.6 million genomes by 2017" (Regalado 2014).4 This may represent a fraction of a percent of
the world’s population, but this number is significant enough that the ethical and legal debate of
genetic information no longer hinges on whether or not this kind of information should be made
available but rather, to whom it should be divulged.
Individuals now have a number of practical reasons to pursue genomic sequencing.
Some patients and their spouses now use this information for "genetic counseling”. This service

2

See Fig. 1 in Appendix.
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The FDA has suspended 23andMe’s health screening test in the United States, pending
confirmation of its accuracy. This service is available however in Canada and the United
Kingdom.
4

See Fig. 2 in Appendix.
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allows carriers of specific genetic traits to consult with medical professionals and interpret
"family and medical histories to assess the chance of disease occurrence or recurrence" in
themselves or their offspring (Uhlmann et al. 2009, 25). Others may one day soon be the first
users of "gene therapy", a practice in which genetic material is "deliberate[ly] administrat[ed] into
a human patient with the intent of correcting a specific genetic defect" ("Human Gene Therapy"
1984, 2). An entirely experimental concept throughout the 20th century, the first gene therapy
treatment was approved for commercial use in Europe in 2012, and the FDA is currently
pending approval of another such treatment here in the United States (Gallagher 2012; "FDA
Grants Breakthrough..." 2014). With a growing number of consumer applications, genetic testing
will gain widespread medical practice throughout the next decade, and with its implementation
will come a host of regulations that will need to be consistent with social norms as well as legal
precedent.

Genetic Information and Equality
Our understanding of human genetics is ever-advancing and their study holds potential
for the treatment of diseases, prevention of heritable disorders, and even the prediction of
certain social outcomes. However with the emergence of this new scientific frontier comes the
concern that "[d]iscoveries [in human genetic science] will challenge the basic concepts of
equality on which our society is based. Once we can say there are differences between people
that are easily demonstrable at the genetic level, then society will have to come to grips with
understanding [this newfound] diversity” (Baltimore 1983). Not unlike the initial discovery of trait
heritability, human genetic information remains culturally tethered to an unfortunate heritage of
eugenics and "racial hygiene”; as correlations are found between genes and certain health
outcomes, societal values of “superiority” and equality may be tested.
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The developed world has come a long way from the days of forced sterilizations, but the
term "social engineering,” and the attitudes associated with it, still persist in institutional circles.
For example Dr. James Watson, the co-discoverer of DNA, was quoted as recently as 2003
saying, "If you are really stupid, I would call that a disease. The lower 10 per cent who really
have difficulty, even in elementary school, what's the cause of it? A lot of people would like to
say, 'Well, poverty, things like that.' It probably isn't. So I'd like to get rid of that, to help the lower
10 per cent" (Black 2003, 442).
This passage illustrates an enduring paradigm in which standards of intelligence and
other social measures are espoused in the name of progress. It represents an interventionist
attitude that proclaims one culture (those in the scientific community) must alter the nature of
another (“the lower 10%”) for the betterment of humankind. One would be hard-pressed to
disagree with the aim of Dr. Watson's statement, but its implications show a flagrant disregard
for the tenets of human equality as well as our ever-changing understanding of humanity’s
capacity to socially “measure” itself. The idea that an individual could be considered "diseased"
by not meeting certain metrics is informed by social determinism– in classifying disorders,
institutions apply systems of values they consider norms which said conditions exist in
opposition to.
Social attitudes have, in the past, manifested in science in unfortunate ways, including
the portrayal of homosexuality and minority traits as "undesirable" elements of "disease" in and
of themselves. Aside from these extreme examples of "scientific racism", preconceived norms
have managed to shape "scientific" paradigms in other less pronounced ways as ultimately "all
disease classification is molded by socially created realities" (Bartlett 2005).
One striking example can be found in the American Psychiatric Association’s Diagnostic
and Statistical Manual of Mental Disorders (hereon abbreviated as "DSM"): entry 309.23
classifies adjustment disorder, with work inhibition as its chief symptom as an insurance-
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recognized diagnosis. The official criteria for this diagnosis– effectively any noticeable reduction
in the patient’s capacity to complete work that was previous performed at some determined
“optimal output” (Bartlett 2005, 29). Indeed the interpretation of the latter is something that could
be considered from multiple philosophical vantage points, but the fact that work inhibition is
considered a diagnosis for a medical disorder is an emphatic reflection of societal cultural
values.
Watson’s determinist views on stupidity as a "disease" conflict with the fact that across
all cultures, ages, and other social strata there exists no universally accepted measurement of
intelligence (Gardner 1983). Until recently low scores on intelligence quotient (IQ) tests were
also listed in the DSM as a means of classifying individuals with “profound mental retardation,”
but one study at the University of Western Ontario found such tests, a Western mainstay in
psychology, to be tone deaf as a single measure of cognitive ability. The authors conclude their
paper by describing a series of pathway-systems in the human brain which they believe may be
responsible for collective intelligence absent the biases of social status and poverty (Hampshire
et al. 2012). One could argue the latter supports Dr. Watson's statement that "stupidity" is
something that can be determined quantifiably in biology. However, given our limited
understanding of epigenetics5 and the fact that socially constructed measures of intelligence
have high potential for obsolescence, this anecdote also illustrates how standards are all but
static. Society's advanced scientific metrics of today may be considered rudimentary or even
entirely false tomorrow. Attempts to base genetic “corrections,” however humane their
methodology may or may not be, on correlations with measurement systems that may not hold
credibility in the future could, not only undermine equality, but the concept of objective scientific
progress as well.

5

The alteration of genetic expression over an individual's lifetime.
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In this regard, eugenics and the attitudes their study was based upon, could be called
the first institutionalized form of genetic discrimination. And though medical science and social
attitudes towards race and sexuality have progressed, the idea of socially deterministic inequity
remains.

Genetic Exceptionalism and the Roots of Discrimination
Few would argue explicitly if society should allow history to influence social enquiry, but
rather the debate often centers around how such history should inform our future ethics and
values. The emergence of genetic science has coincided with concerns that this information
may have a unique ability to interact with social discrimination in ways not previously possible. A
large part of these hypothesized practices hinges on what is known as "DNA
exceptionalism" (Rowe 2015).
"DNA exceptionalism" is the idea that one's genetics can inform others of their future
outcomes. One’s genealogical makeup may reveal predispositions to certain negative health
outcomes and as such is considered more sensitive than health information such as one’s eye
color, height, or past illnesses. With the exception of uniquely debilitating disorders (e.g. Downs
Syndrome, the addition of an entire extra chromosome), cultural misconceptions exist that place
DNA as a paramount prognosticator; code revealing the outcomes of individuals' incomes,
health ailments, and lifespans.
Despite these beliefs, genetic counseling has limited credible uses and DNA isn't able to
identify future behavioral patterns at this time, it isn't necessarily even a reliable predictor of
several well-researched cancers. Indeed certain genes may show an association with tumor
metastasis on a patient-by-patient basis, but rarely is a gene a tell-all of a person’s future (Berns
et al. 1998). Moreover, a recent study at Johns Hopkins Medical Institute found that for 23 of the
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24 diseases their team studied, patients received negative results for "predictive" tests at rates
far higher than the known rates of incidence for the diseases in question, indicating the tests
yielded little useful insight in diagnosis (Roberts et al. 2012). Genetic research has consistently
shown that monozygotic twins, even cloned animal specimens, can exhibit different phenotypes
while having identical embryonic genotypes (Esteller 2008). Such research helped to open the
field of epigenetics i.e. the processes both environmentally and within a living organism which
influence genetic expression, causing profound genetic imprinting across multiple generations
(Esteller 2008).
So if the study of codons can only inform us of relationships in a manner more like
weather forecasts than clockwork, why would DNA be considered such sensitive information?
With this context, attitudes towards human genetics and "genetic exceptionalism" itself may
even sound farcical. At present nobody is going to be able to elicit the outcome of your health or
social behavior in a way comparable to the “pre-crimes” of the Philip K. Dick's Minority Report,
and there seems to be little indication that this is about to change. With that said, the study of
genetics is not isolated from the narratives of "social pathology"; associations between certain
genomic traits and groups, however anecdotal or scientifically unsound, may just as easily lead
to the stigmatization of individuals with these characteristics– and in turn, new identities subject
to discrimination (Tavani 2004). Correlations between certain disorders and risk factors will
largely determine this.
The conception of discrimination is rarely directly tied to scientific inquiry, but rather
preconceived social ideals. Institutional science strives to be objective, but while science can
achieve objective truth mechanically/mathematically, the qualitative interpretation of quantifiable
measurements is never aperspectival (Daston and Galison 2011). Rather the very standards by
which objectivity is regarded are themselves subjective; as Hegel affirmed in his works on social
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conscience, functionally speaking, subjectivity shapes the ethical life and norms of society
(Brownlee 2011).
Assuming medical science were to completely unlock the correct interpretations of all
80,000 genes in the human body- there is little reason to believe that a business which makes
its livelihood on the actuarial wellbeing of clients would not want to use said information to
inform its conduct, even if clientele were to bear expenses inequitably as a result of this
practice. Moreover a health insurance company doesn't need absolute proof of causation to
model correlations for its coverage expenses, if there is some association between a certain
order of codons and a negative health outcome– it is arguably in the business’s best interest to
prevent these losses. However by charging more (or otherwise rejecting) those who may
present significant risk, this discrimination could be seen in some ways as an indirect form
“negative eugenics”. By providing substandard service to those individuals who are seen as
dysgenic factors to a larger business model, insurers would in-effect create a deliberate and
financially driven form of social determinism that would disadvantage particular groups of
customers based on perceived returns.6 Any practice where individuals are given disparate
treatment based on the results of genetic testing is by definition “genetic discrimination”. ("What
is Genetic Discrimination?" 2015).

Contemporary Genetic Discrimination and Its Origins
Genetic discrimination first entered the American lexicon sometime in the early 1980s
with the emergence of modern molecular biology ("'genetic discrimination' - Google Ngrams
Search..."). One of the first scientists to address this in the public sphere was Dr. David

6

It should be noted that the American insurance industry has not endorsed these practices, and
rather in the United Kingdom the insurance industry has in fact placed a voluntary moratorium
on the use of any genomic testing results. This is a discussion of a hypothetical practice, and is
not meant to indicate that insurers are deliberately in favor of eugenic practices.
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Baltimore, recipient of the 1975 Nobel Prize in Physiology and Medicine for his contributions in
the genetics of cancer incidence. In a 1983 interview with U.S. New and World Report, Dr.
Baltimore posed a question which summarized the problems of genetic discrimination-- "[with] a
precise knowledge of heredity...are we going to see pressures [in American society] to channel
people in specific directions because of genetic predispositions?" (Baltimore 1983).
Genetic discrimination law is unique in that, unlike most civil laws, its history has been
more proactive than reactionary. There is a significant body of literature today that empirically
shows some forms of discrimination in the lives and careers of at-risk populations, but up until
the enactment of the 2008 Genetic Information Nondiscrimination Act (GINA), its conception
largely stemmed from public attitudes towards genetic technology. While genetic discrimination
has been documented, much of this record originally stemmed from perceptions rather than civil
or criminal court cases. Early Congressional hearings on the subject were largely dedicated to
polling, rather than case studies or court proceedings (Goh et al. 2013; Otlowski et al. 2012;
"Congressional Hearings..." 2012). Because of this nebulous discourse, in the years up to the
passage of the 2008 law there remained significant concern that legislators were "build[ing]
bureaucracies around phantoms," rather than waiting to better understand what salient role
genetics would play in society (Baltimore 1983). This concern passed altogether when the U.S.
Equal Employment Opportunity Commission filed a discrimination case for "genetic bias" six
years after the introduction of GINA's first draft (H.R. 2728 1995; "EEOC Settles..." 2001; "The
Future of Genetic Nondiscrimination..." 2012). In this particular case the Burlington Northern
Santa Fe Railway (BNSF) sought to commit employees filing for workman's compensation to
blood tests for a gene associated with carpal tunnel syndrome ("EEOC Settles..." 2001). For
many this first EEOC action was blatant confirmation of prior fears, and yet this was a case
already covered by the language of the American Disabilities Act, as the outcome of this
personal genetic test was for a specific disability that would have potentially impacted an
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individual’s employment. If a plaintiff had sued for being denied employment based on a gene
associated with risks of cancer or a future heart condition, rather than a more specific disability,
it remains dubious as to whether or not such a legal challenge would have held up in court at
that time.
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The Genetic Information Nondiscrimination Act (GINA)
Legislative History and Coverage
As genetic services began to affect more patients lives, Congress worked towards
enacting legislation that would prevent discrimination in employment and insurance coverage
based on an individual's genetic makeup. The process of getting this legislation passed was a
decade-long endeavor, with more than 30 drafts brought before the House and Senate between
1995 and 2008 ("Congress.gov"). Both the initial and final drafts of the bill were introduced to
the lower house by Congresswoman Louise Slaughter of New York, who advocated on behalf of
the concerns of a number of social advocacy groups. Chief among these was the Coalition for
Genetic Fairness in Washington, an advocacy alliance founded in 1997 by several nongovernmental organizations including the National Partnership for Women & Families and
National Society for Genetic Counselors (Terry 2011). By the time the Genetic Information
Nondiscrimination Act (GINA) came to a final vote, the coalition's major contributing benefactors
numbered in the hundreds, including several private businesses, medical colleges, disability
advocates, and professional organizations (Terry 2011).
GINA was unanimously endorsed by the Senate on April 24, 2008, and met virtually no
resistance in the House, passing by a margin of 414 to 1 ("Genetic Information
Nondiscrimination Act" 2012). With its passage the Federal government had enacted "legislation
establishing a national and uniform basic standard to fully protect the public from discrimination
and allay their concerns about the potential for discrimination, thereby allowing individuals to
take advantage of genetic testing, technologies, research, and new therapies." ("Full Text of the
Genetic..." 2008).
Under Title II of the Genetic Information Nondiscrimination Act, employers, employment
agencies, labor organizations, and training programs may not refuse to offer employment,
admission, or membership, to an individual as a consequence of said individual's genetic
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makeup. Additionally they may not deprive or categorize employees on these grounds should
these designations "deprive [them] of employment opportunities" (Ibid). Rather than governing
specific genetic testing practices, GINA significantly hinders potential for discrimination by
restricting employers from "request[ing], requir[ing], or purchas[ing]" genetic information on the
individual in question with certain strict exceptions.
These entities may request family medical histories– if they are in compliance with the
Family and Medical Leave Act of 1993, if they are offering health or genetic services to the
individual, if the genetic information is being used to monitor the biological effects of potentially
harmful substances in an OSHA compliant worksite, or if genetic samples are being taken to
maintain background quality control for law enforcement forensics. In all of these scenarios only
medical professionals, genetic counselors, and other authorized personnel administrating these
services may be granted access to this information on an individual basis; all genetic
information furnished to employers must be stored in such a way that each person's files are
individually unidentifiable. In the case of worksite genetic monitoring all individuals must be
granted access to their own results of such tests and can only be committed to them if they
have knowingly been informed of the test and volunteer to take part in it. Fortunately for
employers the law exempts them from wrongdoing if an individual's genetics or family history is
widely published in a public document such as a book, newspaper, magazine, or academic
journal, however the law explicitly states that media such as medical databases and court
proceedings do not fall under this exemption (Ibid).
Additionally Title I of the law specifically addresses insurance discrimination, rendering it
illegal for health insurance providers to base premiums, group or individual, on the genetic
information of a policy’s members. GINA does not however mandate coverage for genetic
testing– rather, individuals will need to prove its necessity to insurers on a case-by-case basis
as with other medical services. Furthermore, the insurer reserves the right to increase premiums
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in the event that a disease becomes manifested in a patient who otherwise previously showed a
predisposition to said disease. The discrimination law applies to genotypic discrimination;
phenotypical diseases, those which a patient has been diagnosed with, still fall under standard
business practices for insurance providers.
GINA applies to virtually all Americans who work for employers or take part in labor
groups and training programs of more than 15 employees, with a couple of additional
exceptions: military personnel, veterans, and Federal employees all fall under their own
respective systems of coverage. Fortunately for servicemen, the military and veterans
administrations have recently issued protocol that enacts similar protections to GINA’s own
(Baruch & Hudson 2008). Federal employees have held such rights since 2000, when President
Bill Clinton issued Executive Order 13145 to "prohibit discrimination in Federal employment
based on genetic information...[applying] to every aspect of Federal employment" ("Executive
Order 13145" 2000).

Outcomes
With this monumental piece of Federal legislation enacted, the question remains– is
there any evidence that GINA has deterred genetically discriminatory practices over the last
seven years, and are there any immediately apparent problems with the law as it stands today?
Moreover, does the law's implementation raise any additional ethical questions about genetic
disclosure practices?
It remains difficult to track the broad implications of GINA as there may not be
widespread public awareness of the rights it grants to individuals (Prince 2015). The only major
quantitative measure we have for its use comes from the EEOC's annual reports of charges
filed against employers; last year 333 cases were filed against employers for genetic
discrimination, comprising 0.4% of the tens of thousands of cases received in total ("Charge
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Statistics FY 1997 Through FY 2014" 2015). Something equally telling is the ability for
individuals to access literature that clearly explains GINA and its implications; when an
employee sues an employer for genetic discrimination, the GINA's enforcement language
stipulates that they must go through their state's EEOC counterpart to either settle the case or
bring it to court ("Full Text of the Genetic..." 2008). As with most legal cases, the latter is typically
a last resort; although EEOC statistics were published as early as 2010, the EEOC did not file
and settle its first GINA-based lawsuit until 2013. In this unprecedented case a corporation,
Fabricut, Inc., made the mistake of mandating a job applicant's family medical history, details
that GINA covers as a form of protected genetic information (Wagner 2013).
The law is also vague as to how the Federal government would handle such a case in
the event that a state was either not honoring their own GINA-related laws or lacked such laws;
this could become a matter of administrative penalties, or a case brought before Federal District
Courts (Prince 2015). This contingency is highly unlikely however, as it appears all states have
at least imposed laws meeting the most stringent requirements of GINA.
Unfortunately, at this time there is no authoritative source on the individual laws of all 50
states. The National Conference of State Legislatures previously maintained a list of all state
laws barring genetic discrimination, but this information has not been updated since GINA was
signed into law, and its completeness up until that time is somewhat questionable ("Genetic
Privacy Laws" 2008). For example, the table lists North Dakota as having no prior state
protections for genetic discriminatory practices and yet there is legislation predating GINA, as
well as health insurance literature, which indicate that this kind of information could not be used
as a "pre-existing condition" prior to the passage of the 2008 law ("Chapter 26.1-36.4" 1995;
Pollitz et al. 2004). Moreover while Pennsylvania and Tennessee have both furnished post-GINA
laws that explicitly state their coverage of this statute, Mississippi's Code proved impossible to
find through the expected online channels (Ch. 89, Sec. 791 PA 2009; Chapter 0780-01-58 TN
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2010). Presently the Mississippi Legislature only discloses a 1972 version of its Code in one
online database, but statutes which include GINA protection are not among these laws nor
legislative bills of the last decade. As it turns out Mississippi ultimately pursued GINA provisions
through a different legal avenue– regulations. The Mississippi Department of Insurance
proposed new regulations to the secretary of state which were implemented in 2009
(Gachaneau 2009). GINA is expressly disclosed in discrimination policies by Mississippi public
institutions however this state appears to lack a readily-accessible database which cites their
legal language ("Policies Regarding Discrimination..." 2014; "The Emergency Food Assistance
Program" 2014). The National Human Genome Research Institute does maintain a Genome
Statute and Legislative Database however, as of writing, this resource yields zero entries for the
State of Mississippi ("The Genome Statute and Legislation Database" 2014). Knowledge of
these laws empowers the citizens they are meant to protect, as such the aforementioned
inconsistencies demonstrate some evidence of a gap in the literature meant to better inform
citizens about GINA and its state counterparts.
The Genetic Information Nondiscrimination Act is limited in scope as well; although it
does consider a number of employment and employment-related organizations in its
protections, its insurance coverage does not extend to life, disability or longterm care
insurances, services provided to consumers that could be significantly impacted by genetic
outcomes. While Congress hasn’t explicitly stated its reasoning for not including such coverage
in the bill, this was likely done to keep the law politically feasible; there was likely little desire to
prolong its approval following more than a decade of unratified drafts (Prince 2015; "The Future
of Genetic Nondiscrimination..." 2012). One must also consider that disability and longterm care
insurance will generally have smaller pools of applicants than health insurance plans, and may
be more likely to regard genetic discrimination laws as a hinderance to their business practices
(Prince 2015).
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While there is some talk of expanding GINA coverage at the Federal level, states are
welcome to expand their discrimination laws, regardless of Congressional inaction, as long as
their laws meet the standards outlined in GINA. Massachusetts is one of these states, with
additional protections explicitly provided in its own respective genetic discrimination legislation.
As of 2015, 19 states have outlawed genetic discrimination practices in longterm care
insurance, as well as 18 for disability insurance, and 14 with statutes preventing the use of
genetic information in premium-setting for life insurance (Ibid). The latter has been approached
in a number of ways, with some states allowing the gathering of genetic information for
underwriting life insurance policies with an individual’s consent, while others have granted life
insurers the right to appeal their use of genetic information on actuarial grounds (Ibid). Two
states, Vermont and New York, have gone a step further and passed laws allowing no insurer of
any kind to use genetic information to set premiums (Ibid).
California's expansion of the Federal statute is perhaps the most comprehensive state
law. CalGINA, ratified in 2011, offers additional protections from the collection of genetic
information for housing and mortgage practices, as well as penal, electoral, and social services.
The law is extremely wide-reaching as it amends the 1959 Unruh Civil Rights Act to include
protections from genetic discrimination in the conduct of "all business establishments of every
kind whatsoever" (Zimring & Bashaw 2001). Additionally CalGINA removes Federal limitations
on the damages a single genetic discrimination case can be filed for ("Full Text of the Genetic..."
2008; "The California Genetic Information..." 2012). Some may indeed argue that this kind of
legal language is excessive and could bring about a disproportional number of cases relative to
the actual incidence of demonstrable genetic discrimination. A quick review of EEOC California
statistics quickly dispels this notion however; genetic discrimination cases represented an
average 0.4 percent of EEOC cases in California since CalGINA's passage, with California
representing on average 8% of all national cases of GINA filings in that same time. When one
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considers that California, the most populous state in the Union, comprises about 12% of the
nation's citizens, it seems entirely reasonable for CalGINA to represent less than that portion of
all national EEOC/GINA filings ("FY 2009 - 2014 EEOC Charge Receipts by State" 2014;
"California; State & County Quickfacts" 2015). Since this law has only been in place for a few
years, future analyses will need to be conducted to determine if this outcome is typical and not
an artifact of its brief history.

Limitations
Arguably the most contentious aspect of genetic laws remains in the disclosure of
genetic information. Unlike one's phenotypic traits such as eye color, weight, or the number of
times an individual has come down with influenza, genomics hold the potential to reveal
information not only about a single individual, but several generations of their relatives as well.
In addition to the privacies provided in GINA, genetic information also falls under the protections
of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which prevents the
release of identifiable information by medical professionals (Gutmann 2012). Ironically, as
people have become more concerned about the privacy of their genetic information,
contemporary medical researchers have made use of increasingly larger data sets to inform
their genomic research, presenting an ethical juxtaposition of legal protections, and the ideal
conditions needed for scientific progress.
Genetic information is sensitive by virtue of its own medium; there are simply no large
stacks of paper lying around with the billions of codons transcribed from each genetic test. As
affirmed in one 2004 abstract on information and communications technology (ICT) and
genetics, in simple terms "there [are] no new genetics without computer science" (Marturano
and Chadwick 2004). The law can protect individual's information symbolically, but the collective
nature of genotypes renders this difficult to accomplish, particularly if one’s relatives have made
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their own data available to the public. Although this may not be a common circumstance, this
scenario holds the potential to undermine the basic principles of laws like HIPAA and GINA. A
research group at MIT was recently able to link identified genetic information with that of
anonymous relatives by using repeated codon patterns on male member Y chromosomes and
online genealogical databases (Gyrmek et al. 2013). Across a number of iterative searches their
team was able to identify otherwise anonymous DNA contributed for research purposes with a
success rate of 18%, and concluded that with additional data this method could be made
significantly more accurate (Gyrmek et al. 2013). At present time this means that at least 1 in 5
individuals whose files are anonymously on record can be found using the information from just
a handful of identified genomes or, in other words, a few hundred identifiable male genomes
have the potential to reveal those of several thousand previously anonymous individuals. It's too
early to say to what extent this risk may grow, but in light of these findings, clearer encryption
policies for ICT data and control-access databases may need to be explored in order to ensure
A) that these findings won't deter volunteers from contributing to genetic medical projects, and
B) that their information can't be used to undermine the privacy of others. With growing interest
in bioinformatics, large genetic databases may be key to translating codon patterns into
phenotypical traits, but until regulatory or technological solutions come into place, individuals
must be informed of the potential risks of disclosing their genes both for their own benefit and
that of the research teams responsible for its storage (McDonnell 2015).
Historically the United States has always been associated with a culture that places the
individual before the collective. These attitudes are emblematic in our hesitance to adopt social
programs, or perhaps our aversion to policies of redistribution; they are equally resonant with
the value placed on privacy. While one's genetic information is their own however, it is also their
parent's, their children's, their family's. Not legally, but biologically-speaking, an individual's
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heritable risk factors for certain diseases and disorders are not solely theirs, but rather can
serve as potential warnings for their relatives.
This leaves an ethical question largely ignored by GINA and the discussions that
surrounded its framing. Should relatives of an individual who is genetically tested have some
right to know if that test yields an outcome that could adversely affect them? There may be a
certain abstract value we place on genetic privacy tied to our conception of dignity, but at what
point do tangible health benefits outweigh this value? Namely, should doctors be allowed to
openly inform persons affected by a genetic carrier gene that might lead to a debilitating or fatal
condition in themselves or their offspring? At this time similar statutes exist in some states for
specific medical contexts; several have "duty to warn" laws for HIV/AIDS diagnoses and severe
psychiatric disorders where the patient is considered a potential threat to others
("Connecticut..." 2014, 32; "Michigan HIV Laws..." 2006, 8; "Mental Health Professionals'..."
2013). Some statutes mandate that doctors inform those affected by these afflictions, others
leave it up to their discretion.
In other contexts where such statutes don't exist, there has been some discussion by
medical professionals over the use "libertarian paternalism," popularized by Harvard economist
Cass Sunstein as "nudge theory" (Sunstein & Thaler 2003; Cohen 2013). The basic concept
behind this theory is that professionals may use positive reinforcement and suggestion to induce
what they perceive to be the most beneficial decision for the individual and others affected by
said individual’s choices (Sunstein & Thaler 2003). Proponents argue that such practices help to
steer patients in the most "welfare-promoting direction" without removing their freedom of choice
(Ibid). Although there has been some acceptance of this approach by the Federal government
and medical communities alike, it relies far more on internal regulations and professional
training than codified policy. This method is especially useful in cases where there is
significantly disparate information between the patient and the doctor. If a medical doctor is not
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obligated to report a health outcome and does not have the contact information of those they
wish to inform, such tactics might induce the patient to relay this information to those who would
be affected by it.
Current HIPAA law does however allow for doctors to inform relatives through one
indirect channel. The language in HIPAA's privacy rule contains a proviso in which medical
information, ergo genetic information, may be relayed if it will be used in the treatment of
another individual ("Under the HIPAA Privacy Rule" 2009). Ultimately this means that if one
doctor has contact with the doctor of another family member or significant other, they can relay
the results of genetic testing to the other physician who then has the discretion to potentially
inform their patient if they believe in their professional opinion that this individual could benefit
from this knowledge ("Under the HIPAA Privacy Rule" 2009; Prince 2015). In this way HIPAA
does have a function which allows important genetic outcomes to reach those who may be
affected by them, but this law is reliant on a couple of factors. Firstly, it assumes that the doctor
of the patient receiving the test believes that the results are important enough to disclose and
that said doctor can readily contact the doctor of the patient's significant other. Barring family
groups with the same health provider, there may be instances where a such contact information
may not be readily available. Secondly, it assumes that the other doctor in this chain of
communication will believe that its disclosure to their patient is the best course of action.
Although both may be informed professionals, a difference of opinion is not unheard of, and
may or may not be in the best interest of those whom this information impacts. While this law
does allow for the transmission of this information without the patient's overt consent, it also
grants the patient the right to request its confidentiality and "[does] not require an explanation
from [said patient] as to the basis for [this] request" ("Under the HIPAA Privacy Rule" 2009; 45
CFR 164.522). For this reason this proviso is somewhat of a catch-22, in that its mechanism for
relaying this information functions, at least in part, on the ignorance of the patient who had
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received the genetic test. If a patient wishes to disclose this information to others, it is theirs to
divulge, however if the patient does not, the only way that a physician can relay this information
is if the patient does not know the details of HIPAA's privacy clause to begin with. This law may
have a function for disclosing medically important information, but it would be difficult to call the
current system ideal. (See Appendix I for further explanation.)
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Policy Recommendations
Rather than simply making this genetic information solely the property of individuals,
even in extenuating circumstances, or placing it in the ethically grey area of the HIPAA privacy
law, I propose that these laws be updated to better reflect the collective nature of genetic
information. France, for example, has created a unique provision by which doctors may report
genetic test results if these results should indicate the patient is a carrier of a fatal disorder or
one that, if expressed, could greatly hinder the independence of their offspring. Should this be
the case, physicians must inform the next of kin and anyone, relatives or spouses, who may be
affected by this condition. The law explicitly states that if these individuals are deceased or
otherwise unreachable, doctors may contact those who are up to 5 generations removed from
the patient to inform them that they too may be carriers of these genes. The law does not give
doctors the authority to mandate that their patients get tested, there is no provision for
mandatory genetic counseling, nor will this information be disclosed to employers or insurers.
Rather such a law provides affected populations with more complete information that empowers
them to alter their lifestyles and consult family planning professionals. Due to the nature of
American law, and the value it places on precedence, such a statute would likely represent a
political firestorm, however, given the collective nature of genetics, and the "duty to report"
precedents set by HIV/AIDs laws and the handling of psychological disorders, this is a concept
that might warrant merit in the American legal system ("Arrête Du 8 Décembre..." 2014).
In much the same way as Congress had hearings over GINA in its initial drafting, it
should also hold such hearings over expansion of the law for disability, longterm care, and life
insurance. The latter has proven to be a contentious issue in state regulations, and unless some
form of standards are set which inform this conduct, these practices will remain ethically
ambiguous and may result in disparate consumer rights across state lines. Similarly consumer
services offering partial genome testing like 23andMe may need to be addressed by Congress
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and other legislative bodies (in the interim) to further define acceptable scenarios for employers,
insurers, and other entities in which the outcomes of these tests are "inadvertently" obtained on
the internet. One problem with GINA and its counterparts stems from the fact that their
disclosure protections solely rely on the intent of employers to "request, require, or purchase"
genetic information ("Full Text of the Genetic..." 2008). Without further refinement of legal
language, modern social media holds the potential to undermine GINA's protections (Ragouissis
et al. 2014). There is presently no Federal statute rendering it illegal for an employer to request
access to their employees' social media accounts and any posts or messages associated with
them. If an individual were to find out from a testing service that they were a carrier for genes
which show a strong affinity for Alzheimers', they might feel compelled to message this
information to potentially affected relatives. If an employer were to come upon this message
without explicitly stating an intent to find this kind of information, there would be little room for
legal recourse, and as intrusive as this practice may seem, there are currently only 11 states
which have made it illegal for employers to ask for social media passwords (Dame 2014). There
are two ways this scenario may be prevented with Federal legislation– firstly, social media could
be amended to those "publicly available" resources which are not exempt from employer
acquisition, currently listed in paragraph 4, subsection b of sections 202-205 of GINA
respectively ("Full Text of the Genetic..." 2008). Secondly, Federal legislation could be passed
which explicitly prevents supervisors from requiring access to an employer's social media as a
condition of employment. It remains illegal under the Computer Fraud and Abuse Act of 1986 for
an employer (or anyone for that matter) to access someone's computer accounts without their
permission, but for some employees the thought of losing their job is simply not an option,
allowing such workplace coercion to continue (18 U.S. Code § 1030). Until the Federal
government or the remaining 39 state legislatures take action on this matter, the most practical
remedy for this situation remains in education- by informing individuals that this situation could
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arise in states where employer social media access is legal, they may choose other (legally
protected) mediums to inform their relatives and partners of their genetic test results.
Its clear from the existing literature, that no matter how GINA and its related policies are
expanded, patients will need something the law cannot give them on its own-- education.
However many times the Congress or state legislatures attempt to rectify the above criticisms in
any manner, their measures will only be as effective if citizens know their rights. Additionally the
medical community and lawmakers must address "[if] widespread clinical application of WGS,
[whole genome sequencing], is medically and ethically appropriate" (Rothstein 2012). One thing
lost on this debate is that GINA, for all of the ways it could be expanded, already offers an
extremely broad definition of genetic information. Any amount of code, any documented family
tree, is covered under this law. At this time it is possible for individuals to get genetic testing and
genetic counseling services that do not make use of whole genome sequencing; for all of the
perceived concerns that exist about the disclosure of genetic information, it's still up to the
consumer to put it out there. The attitudes of the American people toward this technology were
what shaped GINA and its contemporaries, this does not mean the law has to necessarily
redefine these attitudes. People need to know the risks and benefits of the many genetic
services currently available to them; rather consumers could benefit from being able to find all of
this information in a single user-friendly resource. The Presidential Commission for the Study of
Bioethical Issues and the National Human Genome Research Institute both serve their
purposes and both provide information readily available for professionals, the Equal
Employment Opportunity Commission provides useful information for those who need to know
what GINA considers genetic information but for those who just want to know more about their
risks and family histories, the full picture isn't offered in one convenient resource. The least that
can be done is for the Congress Research Service or one of its Federal counterparts to
determine what areas of the this broader system of protective law that Americans do and don't
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understand. From there, we will begin to gain a better picture of the realities of genetic
discrimination, and how we can move forward to support citizens' contributions to medical
research concurrently with reasonable privacy protections.
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Conclusion
Though the Genetic Information Discrimination Act of 2008 (GINA) represents a forwardthinking statute, it's apparent from existing legal and scientific literature that this law will face
numerous challenges in its future implementation. Despite the best efforts of legislators to
endow patients with greater protections, these mechanisms will only be effective as long as they
are widely known. To further empower patients, educational resources must be made available
to them so they may better understand the inherent privacy risks that come with divulging their
genetic information, both for themselves and their relatives.
GINA and its counterpart, the Health Insurance Portability and Accountability Act of 1996
(HIPAA), may address individual protections, but given the similarities of one's own DNA to
those related to them, it makes sense both from an ethical and practical perspective to reevaluate current treatment disclosure policies. In some circumstances it may prove beneficial to
allow doctors to inform other patients of their relatives' tests, regardless of the patient's
willingness to disclose this information, if said tests reveal carrier genes of potentially debilitating
or fatal outcomes.
As human genomes are sequenced in greater numbers over the next decade, it is the
author's hope that this report will inform policymakers of the ethical and legal histories that have
shaped GINA, especially in its limitations where science and law have yet to reach a practical
resolution that addresses the inherently collective properties of genetic information. For science
to be conducive to the greatest societal benefit it must be rooted in ethics of equality, for laws to
most benefit society they must remain based on the latest understandings of science. To best
protect all individuals from disparate treatment, professionals from both fields must continue
facilitate a productive dialogue in the years ahead.
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